MedTrace Logo

Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL

NCT00832221 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2009-09-14

No results posted yet for this study

Summary

The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.

Conditions

Interventions

DRUG

SEROQUEL XR (quetiapine)

repeated dose of oral tablets, 8 times per subject

DRUG

SEROQUEL IR (quetiapine)

repeated dose of oral tablets, 4 times per subject

DRUG

radioligand [11C]raclopride

single dose of iv admin, 5 times per subject

Sponsors & Collaborators

Principal Investigators

  • Ingemar Bylesjö, MD, PhD · AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden

  • Sophia Bengtsson · AstraZeneca R&D, Södertälje, Sweden

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Completion
2009-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00832221 on ClinicalTrials.gov